
Clovis's story ends at chapter 11
Thank you and goodnight Clovis, which has bowed to the inevitable and filed for Chapter 11 protection, ending the debt-driven death spiral the company had been in since 2014. Recent blows had included defaulting on a convertible senior note and a request by the FDA to limit the use of its only approved drug Rubraca to ovarian cancer patients with a BRCA mutation; the latter added to the woes of a product that had fallen way behind Astra/Merck’s Lynparza and Glaxo’s Zejula. These setbacks only intensified the group’s untenable debt position of $438m in convertible senior notes against a market cap of $29m. Arguably, one of the things Clovis did right in its 13 year history was to license radioligand FAP-2286 from 3B Pharmaceuticals. Interest in radiopharmaceuticals has been increasing, a fact recognised by Novartis, which paid $50m up front for the asset, with potential future payments of up to $631m. FAP-2286 will add to Novartis’s existing FAP assets, FAPI-46 and FAPI-74. However, the sale might not be a done deal. Clovis, which is also in discussions to sell Rubraca and other assets, stated that it would be soliciting competing bids for FAP-2286 as part of section 363 of the bankruptcy code.
Clovis convertible senior notes | ||
---|---|---|
Date due | Principal amount, Sept 2022 ($m) | Interest rate |
August 1, 2024 | 85.8 | 4.50% |
August 1, 2024 | 57.5 | 4.50% |
May 1, 2025 | 300.0 | 1.25% |
Total* | 438.3 | |
*Total includes $4.96m credit for debt insurance cost. Source: SEC filings. |